The U.S. & Canada pharmaceutical suppositories market, valued at $0.74 billion in 2023, is projected to reach $1.31 billion by 2035, growing at a CAGR of 4.9% from 2024 to 2035. This steady growth is underpinned by the rising incidence of inflammatory bowel disease (IBD), an expanding geriatric population, and the growing adoption of contract development and manufacturing organizations (CDMOs).
Rising Incidence of IBD Fuels Demand
According to a September 2023 study published by the National Library of Medicine, pediatric-onset IBD is on the rise, increasing by 1.23% annually, with cases expected to grow from 15.6 per 100,000 in 2023 to 18.0 per 100,000 by 2035.
This trend presents a significant opportunity for pharmaceutical companies. Suppositories, which provide localized drug delivery and bypass gastrointestinal challenges, are increasingly seen as a preferred therapeutic option for IBD management. The push toward patient-friendly formulations will encourage innovation in rectal and vaginal suppositories tailored to chronic disease treatment.
Get a Sample Copy of this Report: https://www.alliedmarketresearch.com/request-sample/A325457
What Are Pharmaceutical Suppositories?
Pharmaceutical suppositories are solid dosage forms designed for insertion into body cavities, such as the rectum, vagina, or urethra. Once administered, they melt or dissolve, releasing active pharmaceutical ingredients (APIs) that are absorbed through mucosal tissues.
Common base materials include cocoa butter, glycerinated gelatin, and polyethylene glycol (PEG), chosen for their stability and ability to facilitate controlled release. The manufacturing process involves melting the base, blending it with the API and excipients, molding, and cooling. This drug delivery route is particularly effective when oral administration is impractical or ineffective.
Key Market Takeaways
By Type: Rectal suppositories dominated revenues in 2023, while vaginal suppositories are projected to grow fastest due to rising adoption in women’s health.
By Base Type: The “others” category led in 2023, but progesterone suppositories are expected to expand rapidly, driven by fertility treatments and hormone therapies.
By Prescription Type: Prescribed suppositories held the largest share, though the OTC segment is expected to see the fastest growth, reflecting consumer demand for self-care solutions.
By Distribution Channel: Hospital pharmacies led in 2023, but online providers are poised to grow fastest, supported by e-commerce convenience and discreet purchasing.
By End User: Hospitals & clinics remained the largest users in 2023, while home care settings are projected to expand rapidly, in line with the shift toward patient-managed care.
By Country: The U.S. generated the highest revenue in 2023, but Canada will record the fastest CAGR due to an aging population and rising digestive health disorders.
Market Dynamics
Growing Geriatric Population
A key growth driver is the expanding elderly population. The WHO projects that one in six people will be 60 years or older by 2030. With aging comes higher incidences of constipation, IBD, hemorrhoids, and swallowing difficulties that limit the effectiveness of oral medications.
Suppositories provide an effective alternative, ensuring accurate dosing and improved absorption. They also reduce side effects associated with systemic drug delivery, making them well-suited for elderly patients managing chronic conditions.
Outsourcing to CDMOs
Pharma companies are increasingly outsourcing suppository production to Contract Development and Manufacturing Organizations (CDMOs) such as Trillium Health Care Products, Adragos Pharma, and Cosette Pharmaceuticals. CDMOs bring advanced technology, formulation expertise, and regulatory compliance capabilities, helping companies accelerate market entry while lowering costs.
The rise of generic suppositories further highlights the demand for scalable, cost-effective manufacturing solutions, positioning CDMOs as vital partners in market expansion.
Segmental Insights
Rectal Suppositories: Dominated in 2023 due to broad applications in pain management, constipation, and IBD treatment.
Vaginal Suppositories: Expected to grow fastest, supported by rising use in treating infections, hormone replacement therapy, and fertility care.
Progesterone Suppositories: Anticipated to see the strongest demand growth, particularly in infertility treatments and preterm birth prevention.
OTC Suppositories: Gaining popularity with consumers seeking accessible, cost-effective, and private self-care solutions.
Online Pharmacies: Projected to see strong growth as digital health and e-commerce adoption continue rising.
Home Care Users: Increasingly favored as patients prefer convenient, discreet, and self-administered treatments, including cosmetic suppositories for skin health.
Country Outlook
United States: Leading market share in 2023 due to advanced healthcare infrastructure, strong manufacturer presence, and high adoption rates.
Canada: Expected to grow fastest, fueled by demographic shifts, rising digestive health issues, and improved healthcare infrastructure.
Competitive Landscape
The U.S. & Canada pharmaceutical suppositories market is moderately consolidated, with major players including:
Trillium Health Care Products Inc.
Tri-Pac Indiana, Inc.
DPT Laboratories
Unither
Delpharm Poznań
Noramco Group
Adragos Pharma
LGM Pharma LLC
Cosette Pharmaceuticals, Inc.
Cordenpharma
These companies are focusing on expansion, acquisitions, and CDMO partnerships to enhance their market presence and product pipelines.
Recent Industry Developments
November 2023: Noramco acquired the Cambrex Drug Product Business Unit, expanding its drug formulation and commercial manufacturing capabilities in Canada (Québec) and the U.S. (New Jersey).
March 2022: LGM Pharma invested over $2 million in expanding analytical testing services and launched new suppository manufacturing capabilities to support end-to-end CDMO offerings.
Future Outlook
The pharmaceutical suppositories market in the U.S. and Canada is set for steady and sustainable growth. Rising IBD incidence, a rapidly aging population, and the shift toward home care and self-administered treatments are fueling demand.
At the same time, technological innovations, outsourcing strategies, and digital distribution channels are reshaping how suppositories are manufactured, prescribed, and consumed.
By 2035, the market will not only reach $1.31 billion but also evolve into a more patient-centric, technology-driven, and accessible healthcare segment.
